Expert Financial Analysis and Reporting

Investment Overview and Thesis Antares has carved out an interesting niche in the pharmaceutical industry through building a drug delivery business based on sophisticated injection technologies. Large pharmaceutical companies have always been “oral dosage centric” in their development of dosage forms for their drugs. Their goal has almost always been to find a once a […]

Investment Thesis It has been some time since I have written on Antares (ATRS); in fact my last note was in September 2012. My lack of writing shouldn’t be interpreted as a decline in interest. Antares remains one of my favorite biotechs and one of my largest personal biotech holdings. This is a brief update […]

Investment Opinion I am reiterating my Buy recommendation on Antares which was initiated on December 6, 2011 at a price of $2.77. My price target for 2015 is $11 per share. Reaction to Recent Price Weakness Antares (ATRS) has fallen 27% from its closing price of $5.30 on July 16, to a recent closing price […]

I want to thank people who expressed their appreciation for my research over the years upon learning that I was refunding subscriptions. Some are wondering what I will do from now on. I do not intend to fade away. I just enjoy learning about new companies and technologies too much. I will keep my website […]

Let me say a word about the stock market and the small biopharma stocks that I am recommending. The second half of 2018 and December in particular have been terrible for the market as a whole and horrendous for small biophama stocks. Many of my recommendations are down sharply from recent prices and sometimes from […]

For personal reasons, I am going to be unavailable until October 29. During this interval of silence, there may be some stock moving events on some, but not all, of the companies I am recommending. Let me make a few comments on things that could happen. Northwest Biotherapeutics The two key lead investigators in the […]

Report Overview I periodically update my recommendations and that is the objective of this report. I also spend some time on my analytical approach and investment philosophy. If your investment style is frequent trading, you should not waste your time reading this report. I have four Buy recommendations for stocks that have very significant near […]

Importance of Makena SC to AMAG? AMAG is engaged in a high stakes clinical development program in which it is endeavoring to gain approval of a subcutaneous dosage form of its key drug Makena. Management has guided that sales of Makena reached $333 to $336 million in 2016 (about 63% of total sales) and issued […]

Purpose of this Report I last summarized my stock recommendations in a September 12, 2016 report. There has been little change in my thinking or my recommendations since then on most stocks in my universe, but I did issue a Buy on Bristol-Myers Squibb and a sell on Juno Therapeutics. You may want to revisit […]

PURPOSE OF REPORT Biotechnology investing is characterized by long periods of steady, sometimes frightening declines followed by periods of euphoria. We have been in a deep bear market for emerging biotechnology stocks for over a year that has taken a heavy toll on stock prices. It looks like this may be starting to turn as […]